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Objectives: We evaluated the effect of renal function on clinical failure rates of nitrofurantoin, fosfomycin
and trimethoprim for the treatment of cystitis in primary care.
Methods: Data were retrospectively obtained from 78 Dutch general practitioner (GP) practices between
2013 and 2019. Eligible episodes in patients (>11 years) were those requiring 5 days of nitrofurantoin
(NF5), single-dose fosfomycinetrometamol (FT1), 3 days of trimethoprim (TMP3) for uncomplicated
cystitis, or 7 days of nitrofurantoin (NF7) or trimethoprim (TMP7) for complicated cystitis. Clinical failure
was defined as second antibiotic prescription for cystitis or pyelonephritis within 28 days post-
prescription. Mixed effects regression analysis was used, with patient and GP practice as random ef-
fects and demography, comorbidity, and cystitis history as fixed effects.
Results: Adjusted odds ratios (aORs) for clinical failure per 10mL/min decrease in estimated glomerular
filtration rate (eGFR) were 1.05 (95% CI: 1.01e1.09) for NF5 (n ¼ 24,591), 0.96 (95% CI: 0.92e1.01) for FT1
(n ¼ 5359), 0.98 (95% CI: 0.89e1.08) for TMP3 (n ¼ 1064), 1.05 (95% CI: 1.02e1.09) for NF7 (n ¼ 10,628)
and 1.02 (95% CI: 0.93e1.14) for TMP7 (n ¼ 831). In uncomplicated cystitis and eGFR 60 mL/min, clinical
failures occurred in 14.6% (1895/12 980) of NF5-treated, 20.7% (266/1283) of FT1-treated (aOR versus NF5
1.37, 95% CI 1.18e1.59) and 20.8% (66/318) of TMP3-treated patients (aOR 1.42, 95% CI 1.07e1.87 versus
NF5). In uncomplicated cystitis and eGFR <60 mL/min, FT1 resulted in 16.0% (39/244) and NF5 in 23.3%
clinical failures (110/472), aOR: 0.61, 95% CI: 0.39e0.95).
Conclusions: In eGFR 60 mL/min treatment with fosfomycin or trimethoprim for uncomplicated cystitis
was associated with more clinical failure than treatment with nitrofurantoin, while in eGFR <60 mL/min
nitrofurantoin was associated with more clinical failure than fosfomycinetrometamol. Renal function, if
known, should be considered in the clinical decision-making for cystitis treatment. T. ten Doesschate,
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and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cystitis is a common bacterial infection with an annual inci-
dence of approximately 70 per 1000 in adult women and 10 per
1000 in adult men [1]. In primary care in The Netherlands,
nitrofurantoin is recommended as first-choice oral treatment forrglaan 100, 3584 CX Utrecht,
. ten Doesschate).
r Ltd on behalf of European Society
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al., The effectiveness of nitrof
ogy and Infection, https://doacute uncomplicated cystitis, with fosfomycinetrometamol (fos-
fomycin) as second choice and trimethoprim as third choice [1].
Extended regimens of nitrofurantoin and trimethoprim are first
and second choice respectively in patients with complicated
cystitis, defined as having risk factors for a complicated course
(male gender, diabetes mellitus (DM), urological abnormalities
and immunosuppression) [1].
The efficacy of antimicrobial treatment for cystitis depends
largely on its antimicrobial activity against the pathogen and the
concentration achieved in the urine [2,3]. Nitrofurantoin,of Clinical Microbiology and Infectious Diseases. This is an open access article under
urantoin, fosfomycin and trimethoprim for the treatment of cystitis in
i.org/10.1016/j.cmi.2020.03.001
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and are eliminated by renal excretion, resulting in high concen-
trations in the urine [4e6]. Lower urinary concentrations have been
reported for all three antibiotics in patients with impaired renal
function [4e7]. The concern is that efficacy declines if the drug
concentrations achieved in the urine are insufficient; however,
strong pharmacokinetic-based evidence for this concern is lacking
[6,7]. Retrospective cohort studies failed to demonstrate clear ef-
fects of impaired renal function on the clinical effectiveness of
nitrofurantoin or trimethoprim for the treatment of cystitis [8,9]. To
the best of our knowledge, no such studies have been conducted for
fosfomycin. Consequently, little evidence exists to guide the choice
of antibiotic treatment of cystitis for patients with impaired renal
function.
The aim of this study was to evaluate the effect of renal function
on the occurrence of clinical failure when using nitrofurantoin,
fosfomycin or trimethoprim for the treatment of cystitis. Further-
more, the effectiveness of nitrofurantoin, fosfomycin and trimeth-
oprim for cystitis was compared for normal and decreased renal
function.Methods
Design and data collection
Data were retrospectively obtained from the Julius General
Practitioners' Network (JGPN), consisting of 444 782 patients
receiving care from 78 general practitioner (GP) practices in the
province of Utrecht, The Netherlands, in 2018 [10]. The database
consists of all antibiotic prescriptions to treat cystitis and includes
information on patient characteristics, comorbidities and co-
medication. Diagnoses were coded according to the International
Classification of Primary Care (ICPC). Medication prescriptionswere
coded according to the Anatomical Therapeutic Chemical (ATC)
classification system. Episodes were selected between January 2013
and June 2019 (see Supplementary Material S1 for definitions).Study population
Episodes were eligible for analysis if antibiotic therapy was
prescribed by the GP for the treatment of cystitis according to the
Dutch guideline in patients of at least 12 years of age. Diagnoses
were classified as uncomplicated or complicated according to the
duration of treatment. For uncomplicated cystitis, the guideline
recommends a regimen consisting of 5 days of nitrofurantoin 100
mg extended release (Furabid®) every 12 h or 50mg normal release
(Furadantin®) every 6 h (NF5), a single-dose of fosfomycin 3000mg
(FT1) or a 3-day treatment with trimethoprim 300 mg every 24 h
(TMP3). We excluded cystitis episodes that were treated as un-
complicated cystitis despite the presence of one of the following
risk factors which define it as complicated cystitis: male gender,
pregnancy, DM, urological abnormalities and immunosuppression.
For complicated cystitis, the guideline recommends nitrofurantoin
and trimethoprim in an extended duration of 7 days (NF7 and
TMP7). Patients without documented risk factors but receiving an
extended course were considered as cases of complicated cystitis.
Prescriptions occurring within 28 days of a UTI episode were
considered to represent treatment failures and were therefore not
included as a new cystitis episode.
Renal function was based on the most recent estimated
glomerular filtration rate (eGFR) value measured within 6 months
before or after the prescription date. Episodes were excluded from
the main analysis if no eGFR was measured in this period. The
eGFR was calculated with the chronic kidney diseasePlease cite this article as: ten Doesschate Tet al., The effectiveness of nitrof
relation to renal function, Clinical Microbiology and Infection, https://doepidemiology (CKD-Epi) formula using plasma creatinine values,
age and gender [11].
Outcome
Clinical failure was defined as the prescription of one of the
following antibacterial agents within 28 days of the initial pre-
scription: nitrofurantoin, fosfomycin or trimethoprim, with exclu-
sion of prophylactic use of trimethoprim or nitrofurantoin (>7-day
use), or one of the following antimicrobials in combination with an
ICPC code for cystitis or pyelonephritis: ciprofloxacin, cotrimox-
azole or amoxicillineclavulanic acid. The secondary outcome, py-
elonephritis, was defined as a prescription of ciprofloxacin,
cotrimoxazole or amoxicillineclavulanic acid with an ICPC code for
pyelonephritis within 28 days of the initial prescription.
Statistical analysis
Effect of renal function on clinical failure per treatment regimen
Odds ratios were calculated to determine the association be-
tween the patients' renal function and the risk of clinical failure
(crude analysis) within each of the treatment regimens. Renal
function was analysed in the model as a continuous variable. The
linearity assumption was tested by visual inspection of residuals
plots. eGFR values  90 mL/min were truncated, as no effect is
expected across the range of normal glomerular filtration rates on
the effectiveness of these antibiotics [12]. For the multivariable
analysis, a logistic model with mixed effects was used, incorpo-
rating the correlation among repeated episodes within one patient
and within one GP practice using a random intercept. The adjusted
model was corrected for fixed variables in the population of un-
complicated cystitis: age, socioeconomic status, number of cystitis
prescriptions in the previous year, year of prescription, history of
dementia, cognitive impairment other than dementia, depression, a
consultation because of a (presumed) sexually transmitted disease
(STD) within the prior 6 months, and oral contraceptive use. In the
population of complicated cystitis, we added gender, pregnancy,
solid-organ transplantation, diabetes mellitus, anatomical/func-
tional deficits in the urinary tract or kidney, and immunosuppres-
sive medicine use as confounders. For nitrofurantoin, the dosing
regimen (50 mg normal release every 6 h versus 100 mg slow
release every 12 h) was included as a confounding variable. Fixed
variables were predefined as (potential) risk factors for clinical
failure. Depression and dementia seemed to be associated with a
higher risk of clinical failure in our own data. Oral contraceptive use
and STD presume active sexual behaviour, which is associated with
the occurrence of urinary tract infections. Moreover, STD could
mimic and be misclassified as cystitis and vice versa. Year of pre-
scription as a confounder was included because the use of fosfo-
mycin has increased since 2013, as a consequence of a guideline
change (Supplementary Material S2) with a possible effect on the
risk of clinical failure. Linearity to the log odds was observed for the
continuous values socioeconomic status and age. Missing datawere
imputed using multiple imputation. Two sensitivity analyses were
performed for the primary endpoint in which we applied the same
multivariable model as for the first model. In sensitivity analysis A
we additionally included patients with unknown serum creatinine,
for which we set the eGFR at 90 mL/min. In sensitivity analysis B,
we selected episodes in which the eGFR was measured before or at
the day of prescription.
Effect of treatment regimen on clinical failure rate within strata of
renal function
To compare the effect of antibiotic classes on clinical failure
within strata of renal function, a crude and multivariable mixedurantoin, fosfomycin and trimethoprim for the treatment of cystitis in
i.org/10.1016/j.cmi.2020.03.001
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episodes per patient included for analysis. The same fixed effects as
described above were used with additionally eGFR as a continuous
variable and without patient as random effect. We compared the
short regimens for uncomplicated cystitis (NF5, FT1, TMP3) and
extended regimens for complicated cystitis (NF7, TMP7) in patients
with normal to mild decreased renal function (eGFR 60 mL/min;
Kdigo stage G1 or G2) and in patients with moderately decreased
renal function to kidney failure (eGFR <60 mL/min; Kdigo stage
G3eG5) [13]. We performed the sensitivity analysis A for the
population with eGFR 60 mL/min in which we included a factor
indicating whether eGFR had been measured or not. Sensitivity
analysis B was performed on both renal function populations (eGFR
<60 mL/min and eGFR 60 mL/min).
The models were fit to maximum likelihood using the Laplace
approximation. In all cases, p values < 0.05 were considered sta-
tistically significant. All analyses were performed using R software
(version 3.4.1), using the lme4 package (version 1.1-21).
Ethics
Approval for the study was obtained from the ethical board of




The complete dataset consisted of 164 589 episodes of nitro-
furantoin, fosfomycin and trimethoprim prescriptions. After
applying the exclusion criteria, 42 473 episodes in 21 891 patients
remained for analysis, of which 31 014 (73%) consisted of a short
regimen for uncomplicated cystitis and 11 459 (27%) an extended
regimen for complicated cystitis (Fig. 1). Table 1 gives the patient
characteristics at baseline in the five treatment regimens.Fig. 1. Flowchart for inclusion of episodes from the Julius General Practitioners' Network
province of Utrecht, The Netherlands, between January 2013 and June 2019. NF, nitrofura
filtration rate.
Please cite this article as: ten Doesschate Tet al., The effectiveness of nitrof
relation to renal function, Clinical Microbiology and Infection, https://doSupplementaryMaterial S2 indicates the frequency of antibiotic use
over the past years in this period, with the patient characteristics at
baseline of the population without known renal function (sensi-
tivity analysis A).Effect of renal function on clinical failure per antibiotic regimen
After adjusting for confounders, every 10 mL/min decrease in
eGFR resulted in significantly more clinical failures when using NF5
and NF7, but not when using FT1, TMP3 or TMP7 (Table 2 and
SupplementaryMaterial S3, graphical display). Results were similar
for sensitivity analyses A and B. Decreasing renal function also
tends to higher rates of pyelonephritis for NF5, although there is
wide uncertainty around the estimate (Table 2).Effect of antibiotic class on clinical failure rate within strata of renal
function
In first episodes per patient, clinical failure occurred in 16.3% of
all episodes (3578/21 891): 14.9% after using NF5, 20.0% after using
FT1, 21.4% after using TMP3, 18.1% after using NF7, and 19.7% after
using TMP7 (Supplementary Material S4). Pyelonephritis as a
manifestation of clinical failure occurred in 4.0% of all episodes
(886/21 891): 2.8% after using NF7, 4.1% after using FT1, 3.6% after
using TMP3, 6.6% after using NF7, and 6.4% after using TMP7. In first
episodes in patients in whom no renal function was measured, the
clinical failure rate was 11.0% (3286/29 768) overall and 2.2% (660/
29 768) for pyelonephritis.
The probability of clinical failure in patients with eGFR <60
mL/min was significantly higher when treated with NF5 in com-
parison to FT1 for uncomplicated cystitis (Table 3). In patients with
eGFR 60 mL/min significantly more clinical failures occurred
when using FT1 or TMP3 instead of NF5. Results were similar in
sensitivity analyses A and B, and with pyelonephritis as outcome,
although the latter had larger confidence intervals.(JGPN) consisting of data from 78 general practitioner practices (GP practices) in the
ntoin; FT, fosfomycinetrometamol; TMP, trimethoprim; eGFR, estimated glomerular
urantoin, fosfomycin and trimethoprim for the treatment of cystitis in
i.org/10.1016/j.cmi.2020.03.001
Table 1
Baseline characteristics of cystitis episodes for each antimicrobial regimen
Patient characteristics Treatment (n ¼ 42 473)
Short regimen Extended regimen
NF5 (n ¼ 24,591) FT1 (n ¼ 5359) TMP3 (n ¼ 1064) NF7 (n ¼ 10 628) TMP7 (n ¼ 831)
Age (years)
Median 61 72 73 71 77
Interquartile range 43e75 58e83 55e84 59e81 67e85
Gender
Male (%) NA NA NA 3367 (31.7%) 209 (25.2%)
eGFR (mL/min)
Mean ± SD 85.5 ± 10.1 80.0 ± 17.0 79.4 ± 17.8 78.6 ± 16.1 73.2 ± 19.5
eGFR levels
90 17 686 (71.9%) 3009 (56.1%) 625 (58.7%) 5434 (51.1%) 333 (40.1%)
60e90 5840 (23.7%) 1630 (30.4%) 278 (26.1%) 3586 (33.7%) 295 (35.5%)
30e60 1026 (4.2%) 580 (10.8%) 128 (12.0%) 1501 (14.1%) 172 (20.7%)
0e30 39 (0.2%) 140 (2.6%) 33 (3.1%) 107 (1.0%) 31 (3.7%)
Pregnancy (%) NA NA NA 413 (3.9%) 13 (1.6%)
STD (%) 1176 (4.8%) 348 (6.5%) 56 (5.3%) 612 (5.8%) 66 (7.9%)
Cognitive impairmenta (%) 29 (0.12%) 3 (0.06%) 5 (0.47%) 23 (0.22%) 1 (0.12%)
Dementia (%) 435 (1.8%) 181 (3.4%) 20 (1.9%) 326 (3.1%) 45 (5.4%)
Use of OAC (%) 2637 (10.7%) 420 (7.8%) 93 (8.7%) 379 (3.6%) 19 (2.3%)
Depression (%) 1868 (7.6%) 410 (7.7%) 94 (8.8%) 691 (6.5%) 53 (6.4%)
Diabetes mellitus (%) NA NA NA 5089 (47.9%) 448 (53.9%)
Urological abnormalities (%) NA NA NA 418 (3.9%) 20 (2.4%)
Use of immunosuppressants (%) NA NA NA 372 (3.5%) 36 (4.3%)
Socioeconomic status scoreb
Median 0.19 0.19 0.32 0.19 0.19
Interquartile range e0.19e1.24 e0.12e1.10 e0.48e1.31 e1.16e0.97 e1.16e0.97
N episodes of cystitis previous yearc
Median 0 1 1 0 1
Interquartile range 0e1 0e2 0e2 0e1 0e2
eGFR, estimated glomerular filtration rate; STD, sexually transmitted disease, OAC, oral anticonception; NF5, nitrofurantoin 5-day treatment; FT1, fosfomycinetrometamol 1-
day treatment; TMP3, trimethoprim 3-day treatment; NF7, nitrofurantoin 7-day treatment; TMP7, trimethoprim 7-day treatment.
a Other than dementia.
b Socioeconomic state ranges from e7 to þ7 and is estimated on the neighbourhood the patient lives (postal code) (271 missing).
c Number of prescriptions for cystitis or pyelonephritis in the past 365 days before the episode (four missing).
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In patients with uncomplicated and complicated cystitis
treated with nitrofurantoin, an association was seen between
decreased renal function and clinical failure, which was not seen
in those treated with fosfomycin or trimethoprim. Treatment
with a single dose of fosfomycin for uncomplicated cystitisTable 2
The effect of every 10 mL/min decrease in estimated glomerular filtration rate (eGFR) on
Therapy Patients Clinical failure Crude analysis Multivariable anal
Number Number (%) Odds ratio (95% CI) Odds ratio (95% CI
NF5 24 591 4245 (17.3) 1.02 (1.02e1.03)b 1.05 (1.01e1.09) c
FT1 5359 1235 (23.0) 1.00 (0.99e1.00) 0.96 (0.92e1.01)
TMP3 1064 248 (23.3) 1.00 (0.98e1.01) 0.98 (0.89e1.08)
NF7 10 628 2113 (19.9) 1.01 (1.01e1.02)b 1.05 (1.02e1.09)c
TMP7 831 201 (24.2) 0.99 (0.98e1.01) 1.02 (0.93e1.14)
NF5, nitrofurantoin 5-day treatment; FT1, fosfomycinetrometamol 1-day treatment; T
trimethoprim 7-day treatment.
a Adjusted for the following confounding variables: age, year of prescription, a con
impairment other than dementia, oral contraceptive use, depression, dementia, socioecon
slow-release nitrofurantoin formulation, with as random effects the patient and the gener
diabetes mellitus, urological abnormalities, use of immunosuppressants, solid-organ trans
as above with addition of patients with unknown serum creatinine, for whom we set th
confounders as above with selection of patients in whom the eGFR was measured before
outcome pyelonephritis, multivariable analysis using the same confounders as above wi
b p < 0.001.
c p < 0.01.
d p < 0.05.
e Due to convergence problems when adjusting for both patient and the general pra
general practitioners' practice as random effect.
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relation to renal function, Clinical Microbiology and Infection, https://doresulted in less clinical failures in patients with eGFR <60
mL/min compared to 5 days of nitrofurantoin. In contrast, in
patients with eGFR 60 mL/min nitrofurantoin appeared more
effective than fosfomycin or trimethoprim for uncomplicated
cystitis. The latter is in line with the results of a trial in which
nitrofurantoin for 5 days was more efficacious than a single dose
of fosfomycin for uncomplicated cystitis, although athe odds ratio of clinical failure within 28 days post-prescription
ysisa Sensitivity analysis Aa Sensitivity analysis Ba Secondary outcome
pyelonephritisa
) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
1.05 (1.01e1.09)c 1.04 (1.00e1.09)d 1.34 (0.96e1.87)
0.97 (0.93e1.02) 0.93 (0.88e0.98)d 0.83 (0.58e1.20)
0.96 (0.88e1.05) 0.97 (0.87e1.08) 1.12 (0.89e1.41)
1.01 (0.98e1.04) 1.05 (1.01e1.10)d 1.00 (0.93e1.06)e
0.99 (0.93e1.05) 0.99 (0.88e1.12) 0.86 (0.73e1.02)
MP3, trimethoprim 3-day treatment; NF7, nitrofurantoin 7-day treatment; TMP7,
sultation because of sexual transmitted disease in the prior half year, cognitive
omic status, number of episodes of cystitis in the previous year, the use of normal or
al practitioners practice. For complicated cystitis additionally for gender, pregnancy,
plantation. Sensitivity analysis A, multivariable analysis using the same confounders
e eGFR to 90 mL/min; sensitivity analysis B, multivariable analysis using the same
or at the moment of prescription; patients with unknown eGFR were not included;
th the outcome pyelonephritis as manifestation of clinical failure.
ctitioners' practice as random effects, only first episodes were analysed with only
urantoin, fosfomycin and trimethoprim for the treatment of cystitis in
i.org/10.1016/j.cmi.2020.03.001
Table 3





Therapy Crude analysis Multivariable analysis Sensitivity analysis Aa Sensitivity analysis Ba Outcome pyelonephritisa
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
<60 Uncomplicated FT1 vs NF5 0.63 (0.42e0.94)b 0.61 (0.39e0.95)b NA 0.73 (0.46e1.12) 0.67 (0.25e1.76)
TMP3 vs NF5 1.05 (0.58e1.92) 0.96 (0.51e1.82) NA 0.53 (0.25 e1.16) 0.28 (0.04e2.23)
TMP3 vs FT1 1.68 (0.87e3.25) 1.59 (0.79e3.21) NA 0.73 (0.32e1.68) 0.42 (0.05e3.62)
Complicated TMP7 vs NF7 0.89 (0.49e1.59) 0.89 (0.48e1.65) NA 0.62 (0.32e1.22) 1.50 (0.66e 3.42)
60 Uncomplicated FT1 vs NF5 1.53 (1.33e1.77)c 1.37 (1.18e1.59)c 1.29 (1.14e1.46)c 1.35 (1.16e1.58)c 1.52 (1.13e2.06)b
TMP3 vs NF5 1.53 (1.16e2.02)d 1.42 (1.07e1.87)b 1.55 (1.26e1.92)c 1.48 (1.08e2.02)c 1.32 (0.74e2.36)
TMP3 vs FT1 1.00 (0.74e1.36) 1.03 (0.76e1.40) 1.20 (0.95e1.53) 1.09 (0.78e1.53) 0.87 (0.47e1.63)
Complicated TMP7 vs NF7 1.15 (0.82e1.62) 0.99 (0.69e1.41) 0.99 (0.72e1.35) 1.06 (0.74e1.51) 0.83 (0.44e1.56)
NF5, nitrofurantoin 5-day treatment; FT1, fosfomycinetrometamol 1-day treatment; TMP3, trimethoprim 3-day treatment; NF7, nitrofurantoin 7-day treatment; TMP7,
trimethoprim 7-day treatment.
a Adjusted for the following confounding variables: age, year of prescription, a consultation because of sexual transmitted disease in the prior half year, cognitive
impairment other than dementia, oral contraceptive use, depression, dementia, socioeconomic status, number of episodes of cystitis in the previous year, the use of normal or
slow-release nitrofurantoin formulation, with as random effects general practitioners practice. For complicated cystitis additionally for gender, pregnancy, diabetes mellitus,
urological abnormalities, use of immunosuppressants, solid-organ transplantation. Sensitivity analysis A, multivariable analysis using the same confounders as above with
addition of patients with unknown serum creatinine, for whom we set the eGFR to 90 mL/min; sensitivity analysis B, multivariable analysis using the same confounders as
above with selection of patients in whom the eGFR was measured before or at the moment of prescription; outcome pyelonephritis, multivariable analysis using the same
confounders as above with the outcome pyelonephritis as manifestation of clinical failure.
b p < 0.05.
c p < 0.001.
d p < 0.01.
T. ten Doesschate et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 5nitrofurantoin schedule of 100 mg three times daily with normal
release was used in this trial [14].
Based on the pharmacokinetic profile, it could have been ex-
pected that renal function impacted the efficacy of nitrofurantoin
more than that of fosfomycin or trimethoprim. All three antibiotics
are eliminated by glomerular filtration [15e18]; however, in
contrast to nitrofurantoin, high urinary concentrations of trimeth-
oprim and fosfomycin are reached after administration of the
registered dose [19e23]. The effect of decreased renal function on
the efficacy of cystitis treatment has not been thoroughly investi-
gated as prior randomized controlled trials excluded patients with
decreased renal function [14,24e28]. A retrospective cohort study
investigated the effect of eGFR on the effectiveness of nitro-
furantoin compared to trimethoprim; eGFR <80 mL/min/1.73m2
was not associated with decreased effectiveness of nitrofurantoin
or trimethoprim, although confidence intervals were wide [9]. In
the same study, a significant association between decreased renal
function (eGFR <50 mL/min/1.73m2) and the occurrence of pul-
monary reactions leading to hospitalization was found for nitro-
furantoin. In another retrospective cohort study on the
effectiveness of nitrofurantoin for cystitis in males the odds ratio of
clinical failure was 1.13 (95% CI: 1.04e1.23) for every 10 mL/min
decrease in eGFR, which is in line with the odds ratio of 1.05 (95%
CI: 1.01e1.09) derived in this study [8]. We are not aware of clinical
studies that have evaluated the effect of renal function on the
effectiveness of fosfomycin for cystitis.
The population in the current study is relatively old, with sub-
stantial comorbidities, and therefore serum creatinine levels were
available. The overall clinical failure rate was high (16.3%), as
compared to episodes in generally younger patients with unknown
renal function (11.0%). We do not suggest routine testing of renal
function in all patients with cystitis, but only in those cases where
renal impairment is suspected. In patients with uncomplicated
cystitis, if renal impairment is not suspected, the renal function
may be assumed adequate; in fact, our results did not change when
patients with unknown eGFR were included in the normal renal
function group.
Our study has limitations, the most important being its retro-
spective design. Although the JGPN database provides reliable
quantitative estimates of demographic data, drug prescriptions
(ATC codes), symptoms (ICPC codes) and laboratory values, detailedPlease cite this article as: ten Doesschate Tet al., The effectiveness of nitrof
relation to renal function, Clinical Microbiology and Infection, https://doinformation on dipstick results, treatment compliance, microbio-
logical cultures, and considerations for clinical decision-making are
missing [10]. However, Dutch GPs usually confirm the presence of
cystitis with dipstick before prescribing antibiotics, which increases
the likelihood that true cystitis episodes were treated [29]. In
particular, severe clinical failure rates may have been under-
estimated as prescription data from hospitals and out-of-office GP
services were lacking. However, in The Netherlands only 6% of total
antibiotic prescriptions in primary care occur in out-of-office hours
[30,31].
A second limitation is that confounding by indication could not
be excluded when comparing the different treatment options, as
nitrofurantoin is the first choice for cystitis according to the treat-
ment guideline and nitrofurantoin is contraindicated in patients
with a severely decreased renal function (GFR <30 mL/min) [1].
Although we only included first episodes of cystitis, and we
adjusted for the number of cystitis prescriptions in the previous
year, residual confounding is possible. If so, we expect bias in favour
of NF5 and NF7.
Third, the treatment regimens and definitions of cystitis as used
in this study comply with Dutch primary care guidelines. Gener-
alizability of the results may therefore be limited for countries or
healthcare settings where different definitions apply. Nevertheless,
we expect that the effect of renal function on clinical effectiveness
is to some extent generalizable to the therapeutic use of nitro-
furantoin, fosfomycin and trimethoprim for urinary tract infections.
Fourth, in some patients the renal function was estimated on
eGFR values that were measured after the prescription date, which
is inconsistent with the aetiological nature of the study and does
not represent the clinical decision-making. Therefore, sensitivity
analysis B was performed that only included eGFRmeasured within
6 months prior to the episode, which resulted in similar findings.
Fifth, the results of our study were not corrected for multiple
testing, because distinct hypotheses were tested for separate anti-
biotic regimens, and the comparisons between the effectiveness of
cystitis regimens were a derivative of these results. However, there
might be a risk of type I errors, and independent confirmation of
our results is required.
In conclusion, the results of this study indicate that impaired
renal function reduces the effectiveness of nitrofurantoin for
treatment of cystitis, which could have clinically relevanturantoin, fosfomycin and trimethoprim for the treatment of cystitis in
i.org/10.1016/j.cmi.2020.03.001
T. ten Doesschate et al. / Clinical Microbiology and Infection xxx (xxxx) xxx6implications for the patient. Consequently, fosfomycin might
be more effective than nitrofurantoin in patients with eGFR <60
mL/min. These findings should be considered in the clinical
decision-making for treatment of cystitis. New trials, including
patients with impaired renal function, are needed to confirm these
findings. Next, more studies are warranted investigating the phar-
macokinetic/pharmacodynamic profile of nitrofurantoin, fosfomy-
cin and trimethoprim for the treatment of cystitis in patients with
impaired renal function.Author contributions
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